🔬 Developing novel therapeutics to treat Alzheimer's Disease
🧬 Targeting the Amylin Receptor — a breakthrough approach in AD research
💊 Advancing both Peptide & Small Molecule drug candidates
🏫 Founded from pioneering research at the University of Alberta
🧪 Screened over 7 million compounds to identify Alzheimer's blockers
🐭 Proven efficacy in Alzheimer's mouse models — improved memory & learning
🤝 Collaborating with world-leading scientists & academic institutions
🌍 Developing disease-modifying therapies for early & late-stage Alzheimer's
🏆 Led by award-winning neurologist Dr. Jack Jhamandas (30+ yrs expertise)
🔭 Using Cryo-EM to understand drug-receptor binding mechanisms
🔬 Developing novel therapeutics to treat Alzheimer's Disease
🧬 Targeting the Amylin Receptor — a breakthrough approach in AD research
💊 Advancing both Peptide & Small Molecule drug candidates
🏫 Founded from pioneering research at the University of Alberta
🧪 Screened over 7 million compounds to identify Alzheimer's blockers
🐭 Proven efficacy in Alzheimer's mouse models — improved memory & learning
🤝 Collaborating with world-leading scientists & academic institutions
🌍 Developing disease-modifying therapies for early & late-stage Alzheimer's
🏆 Led by award-winning neurologist Dr. Jack Jhamandas (30+ yrs expertise)
🔭 Using Cryo-EM to understand drug-receptor binding mechanisms
Contact Us
Partners

Backed by institutionsthat matter.

Egeiro counts with the support of numerous government organizations and academic institutes committed to accelerating our research and development efforts.

 
  • University Hospital Foundation
The University Hospital Foundation (UHF) is a key collaborator in accelerating Egeiro’s research and development efforts. Through a model of venture philanthropy—made possible by the unwavering generosity of Foundation donors—this relationship highlights a shared commitment to addressing clinical needs and exploring pathways for new healthcare solutions. To learn more about the Foundation’s impact, visit givetouhf.ca.
  • University of Alberta
Dr. Jhamandas’s initial discovery work occurred at the University of Alberta and the IP was later spun off into Egeiro Pharmaceuticals. Academic research activities related to his work with the amylin receptor continue within the University, leveraging the expertise from its scientific experts and teams.
  • Li Ka Shing Applied Virology & Institute of Virology

Egeiro has leveraged the expertise in computational drug design and synthetic and medicinal chemistry at the Applied Virology Institute, the translation and commercialization hub of Li Ka Shing Institute of Virology, to screen, identify and synthesize small molecules able to inhibit the activity of the amylin receptor.

  • Applied Pharmaceutical Innovation (API)

Egeiro is collaborating with Applied Pharmaceutical Innovation (API), one of Canada’s largest not-for-profit life sciences commercialization organizations. Supporting the full development lifecycle from early discovery to clinical and commercial manufacturing, API helps bring life-saving innovations to market.

  • InScitech

Dr. Elizabeth Vadas, leveraging her extensive drug development and medicinal chemistry expertise at Merck, has provided Egeiro with critical input in terms of evaluation methodologies, characterization and lead candidate selection and formulation development strategy.

Scroll to Top